ArticleScientific reports2021
Precise enhancement quantification in post-operative MRI as an indicator of residual tumor impact is associated with survival in patients with glioblastoma.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- AI for prognosis and treatment stratification in glioblastoma neurosurgery: a systematic review.Journal of neuro-oncology · 2026Pooled it
- Consequences of Hypoxic Events, Necrosis, and Microvascular Density, in Astrocytoma IDH-Mutant, CNS WHO Grade 4.Medical sciences (Basel, Switzerland) · 2025Article
- Radiomics-based quantification of tumor infiltration in the non-enhancing peritumoral region on postoperative MRI is associated with survival in glioblastoma.Scientific reports · 2025Article
- Machine learning-based integration of dosiomics and pre-radiotherapy multimodal MRI radiomics for survival stratification in patients with glioblastoma multiforme.Radiation oncology (London, England) · 2025Article
- Correlation of contrast-enhancing tumor region on pre-radiotherapy MRI with overall survival in glioblastoma.European journal of medical research · 2025Article
- Article
- Multidisciplinary, Clinical Assessment of Accelerated Deep-Learning MRI Protocols at 1.5 T and 3 T After Intracranial Tumor Surgery and Their Influence on Residual Tumor Perception.Diagnostics (Basel, Switzerland) · 2025Article
- Comparative Clinical-Imaging and Histogenetic Analysis Between Astrocytoma IDH-Mutant Grade 4 and Glioblastoma IDH-Wildtype-Is There Really a Worse One?Diagnostics (Basel, Switzerland) · 2025Article
- Radiomics for residual tumour detection and prognosis in newly diagnosed glioblastoma based on postoperative [Scientific reports · 2024Article
- Artificial Intelligence Analysis Using MRI and PET Imaging in Gliomas: A Narrative Review.Cancers · 2024Review
- Resection of positive tissue on methionine-PET is associated with improved survival in glioblastomas.Brain and behavior · 2023Article
- Article
- Segmentation of glioblastomas in early post-operative multi-modal MRI with deep neural networks.Scientific reports · 2023Article
- Predicting the WHO Grading of Pediatric Brain Tumors Based on Their MRI Appearance: A Retrospective Study.Cureus · 2023Article
- Comparison of EPI DWI and STEAM DWI in Early Postoperative MRI Controls After Resection of Tumors of the Central Nervous System.Clinical neuroradiology · 2023Article
- Advanced Magnetic Resonance Imaging in the Evaluation of Treated Glioblastoma: A Pictorial Essay.Cancers · 2023Review
- Timing of Early Postoperative MRI following Primary Glioblastoma Surgery-A Retrospective Study of Contrast Enhancements in 311 Patients.Diagnostics (Basel, Switzerland) · 2023Article
- T1-Weighted Contrast Enhancement, Apparent Diffusion Coefficient, and Cerebral-Blood-Volume Changes after Glioblastoma Resection: MRI within 48 Hours vs. beyond 48 Hours.Tomography (Ann Arbor, Mich.) · 2023Article
- DeepEOR: automated perioperative volumetric assessment of variable grade gliomas using deep learning.Acta neurochirurgica · 2023Article
- Advances in the In Vivo Quantitative and Qualitative Imaging Characterization of Gliomas.Cancers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma is the most common primary brain tumor. Standard therapy consists of maximum safe resection combined with adjuvant radiochemotherapy followed by chemotherapy with temozolomide, however prognosis is extremely poor. Assessment of the residual tumor after surgery and patient stratification into prognostic groups (i.e., by tumor volume) is currently hindered by the subjective evaluation of residual enhancement in medical images (magnetic resonance imaging [MRI]). Furthermore, objective evidence defining the optimal time to acquire the images is lacking. We analyzed 144 patients with glioblastoma, objectively quantified the enhancing residual tumor through computational image analysis and assessed the correlation with survival. Pathological enhancement thickness on post-surgical MRI correlated with survival (hazard ratio: 1.98, p < 0.001). The prognostic value of several imaging and clinical variables was analyzed individually and combined (radiomics AUC 0.71, p = 0.07; combined AUC 0.72, p < 0.001). Residual enhancement thickness and radiomics complemented clinical data for prognosis stratification in patients with glioblastoma. Significant results were only obtained for scans performed between 24 and 72 h after surgery, raising the possibility of confounding non-tumor enhancement in very early post-surgery MRI. Regarding the extent of resection, and in agreement with recent studies, the association between the measured tumor remnant and survival supports maximal safe resection whenever possible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.